Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A412452-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $259.90 | |
A412452-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $399.90 | |
A412452-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $119.90 | |
A412452-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,035.90 |
ADC Cytotoxin
Synonyms | N-(2-{[4-(1,1-difluoroethyl)-1,3-oxazol-2-yl]methyl}-2H-1,2,3-triazol-4-yl)-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide | N-[2-[[4-(1,1-difluoroethyl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide | A |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | ACT-389949 is a potent, selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX) with EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for inflammatory disorders. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of FPR2/ALX |
Product Description | Information ACT-389949 is a potent, selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX) with EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for inflammatory disorders. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | N-[2-[[4-(1,1-difluoroethyl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide |
---|---|
INCHI | InChI=1S/C20H18F2N6O3/c1-11-5-4-6-13(7-11)18-17(24-12(2)31-18)19(29)26-15-8-23-28(27-15)9-16-25-14(10-30-16)20(3,21)22/h4-8,10H,9H2,1-3H3,(H,26,27,29) |
InChi Key | PBTWPEDVIMHJEO-UHFFFAOYSA-N |
Canonical SMILES | CC1=CC(=CC=C1)C2=C(N=C(O2)C)C(=O)NC3=NN(N=C3)CC4=NC(=CO4)C(C)(F)F |
Isomeric SMILES | CC1=CC(=CC=C1)C2=C(N=C(O2)C)C(=O)NC3=NN(N=C3)CC4=NC(=CO4)C(C)(F)F |
Alternate CAS | 1258417-54-7 |
PubChem CID | 49834265 |
MeSH Entry Terms | 2-methyl-5-m-tolyloxazole-4-carboxylic acid (2-(4-(1,1-difluoroethyl)oxazol-2-ylmethyl)-2H-(1,2,3)triazol-4-yl)amide;ACT-389949 |
Molecular Weight | 428.4 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
A2426242 | Certificate of Analysis | Dec 25, 2023 | A412452 |
A2426243 | Certificate of Analysis | Dec 25, 2023 | A412452 |
A2426244 | Certificate of Analysis | Dec 25, 2023 | A412452 |
A2426245 | Certificate of Analysis | Dec 25, 2023 | A412452 |
A2426247 | Certificate of Analysis | Dec 25, 2023 | A412452 |
Solubility | Solubility (25°C) In vitro Ethanol: mg/mL |
---|
1. Stalder AK, Lott D, Strasser DS, Cruz HG, Krause A, Groenen PM, Dingemanse J. (2017) Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.. Br J Clin Pharmacol, 83 (3): (476-486). [PMID:27730665] [10.1021/op500134e] |